PMID- 8943170
OWN - NLM
STAT- MEDLINE
DCOM- 19970409
LR  - 20190826
IS  - 0364-2313 (Print)
IS  - 0364-2313 (Linking)
VI  - 21
IP  - 1
DP  - 1997 Jan
TI  - Efficacy and safety of a low-molecular-weight heparin and standard unfractionated 
      heparin for prophylaxis of postoperative venous thromboembolism: European 
      multicenter trial.
PG  - 2-8; discussion 8-9
AB  - A randomized, double-blind multicenter trial was performed to compare the safety 
      and efficacy of a new low-molecular-weight heparin (LMWH) (LU 47311, Clivarine) 
      and standard unfractionated heparin for the prophylaxis of postoperative venous 
      thromboembolism. Altogether 1351 patients scheduled to undergo abdominal surgery 
      were included. Main outcome measures included the incidence of thromboembolic 
      events (deep vein thrombosis, pulmonary embolism, or both) and bleeding 
      complications, including wound hematoma. A total of 655 patients received 1750 
      anti-Xa IU of LMWH plus a placebo injection daily; 677 patients received 5000 IU 
      of unfractionated heparin (UFH) twice a day. Both drugs were found to be equally 
      effective, as 4.7% of patients in the LMWH group and 4.3% in the UFH group 
      developed postoperative thromboembolic complications. However, the incidence of 
      bleeding complications was significantly reduced in the LMWH group: 55 (8.3%) 
      patients in the LMWH group and 80 (11.8%) in the UFH group developed bleeding 
      complications, a relative risk (RR) of 0.70 (95% CI 0.51-0.97;p = 0.03); wound 
      hematoma occurred in 29 (4.4%) of the LMWH group compared with 55 (7.7%) in those 
      in the UFH group for an RR of 0.57 (95% CI 0.37-0.88;p = 0.01). This study 
      confirmed that a very low dose of 1750 anti-Xa IU daily of this new LMWH is as 
      effective as 10,000 IU of UFH for preventing postoperative deep vein thrombosis. 
      At this dose its administration is associated with a significant reduction in the 
      risk of bleeding including wound hematoma.
FAU - Kakkar, V V
AU  - Kakkar VV
AD  - Thrombosis Research Institute, Emmanuel Kaye Building, Manresa Road, Chelsea SW3 
      6LR, London, UK.
FAU - Boeckl, O
AU  - Boeckl O
FAU - Boneu, B
AU  - Boneu B
FAU - Bordenave, L
AU  - Bordenave L
FAU - Brehm, O A
AU  - Brehm OA
FAU - Brucke, P
AU  - Brucke P
FAU - Coccheri, S
AU  - Coccheri S
FAU - Cohen, A T
AU  - Cohen AT
FAU - Galland, F
AU  - Galland F
FAU - Haas, S
AU  - Haas S
FAU - Jarrige, J
AU  - Jarrige J
FAU - Koppenhagen, K
AU  - Koppenhagen K
FAU - LeQuerrec, A
AU  - LeQuerrec A
FAU - Parraguette, E
AU  - Parraguette E
FAU - Prandoni, P
AU  - Prandoni P
FAU - Roder, J D
AU  - Roder JD
FAU - Roos, M
AU  - Roos M
FAU - Ruschemeyer, C
AU  - Ruschemeyer C
FAU - Siewert, J R
AU  - Siewert JR
FAU - Vinazzer, H
AU  - Vinazzer H
FAU - Wenzel, E
AU  - Wenzel E
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - World J Surg
JT  - World journal of surgery
JID - 7704052
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 5R0L1D739E (reviparin)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Heparin/adverse effects/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/adverse effects/*therapeutic use
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/mortality/*prevention & control
MH  - Pulmonary Embolism/mortality/prevention & control
MH  - Risk Factors
MH  - Thromboembolism/*prevention & control
MH  - Thrombophlebitis/epidemiology/prevention & control
MH  - Treatment Outcome
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.1007/s002689900185 [doi]
PST - ppublish
SO  - World J Surg. 1997 Jan;21(1):2-8; discussion 8-9. doi: 10.1007/s002689900185.